UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruiting
18 years - 99 years
All
Phase 3
5 participants needed
1 Location

Brief description of study

The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.

Detailed description of study

The loss of enjoyment of food and weight loss has shown to decrease the quality of life for cancer patients. Additionally, poor eating and weight loss affects patients’ overall health, making them increasingly tired and more likely to experience side effects from their cancer treatments. Some patients have to take lower doses of cancer-fighting treatments or stop using them altogether.
Anamorelin HCl, works by mimicking a naturally occurring substance in the body that causes increased appetite and weight gain.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: BMI <20,Lung Cancer,Weight Loss,Loss of Appetite
  • Age: 18 years - 99 years
  • Gender: All

  1. Female or male ≥18 years of age
  2. Documented diagnosis of  Stage III or IV Non-Small Cell Lung Cancer.
  3. Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months  prior to screening.

Updated on 19 Feb 2024. Study ID: 832183

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.